Navigation Links
Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
Date:3/28/2013

1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding when it will submit a CTA for OMS721 and begin clinical trials; that OMS721 may be delivered subcutaneously and the frequency of dosing; the diseases that may be treated by OMS721; the potential competitive advantages of OMS721; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced that it will release its year-end ... 2015 on Friday, September 4, 2015. ... call and live webcast for investors, analysts and other ...
(Date:8/27/2015)... , Spain and CAMBRIDGE, Mass. , Aug. ... be presenting at the Rodman & Renshaw 17th Annual Global ... Held at the St. Regis Hotel, ORYZON will be represented ... Dr. Buesa will present ... EDT, at the Fontainebleau Room (2nd Floor).  The company is ...
(Date:8/27/2015)... 2015 The global compression ... 3.96 billion by 2022, according to a new report ... venous disorders such as deep vein thrombosis, leg ulcers, ... the key driver.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757) , ... also expected to boost market growth over the forecast ...
Breaking Medicine Technology:DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... Mass., Jan. 23, 2012  Boston Scientific Corporation (NYSE: ... District of New Jersey has found all the asserted patents ... invalid and entered judgment in favor of Boston Scientific. ... Johnson alleged that Boston Scientific,s PROMUS® Everolimus-Eluting Coronary Stent System ...
... Premier Research Group announces the appointment of Etienne Drouet ... this position, Mr. Drouet will play a leading role ... Premier Research,s growing portfolio of oncology business. ... oncology acumen serving the needs of our customers," said ...
Cached Medicine Technology:Boston Scientific Announces Favorable Ruling in Patent Infringement Case 2Boston Scientific Announces Favorable Ruling in Patent Infringement Case 3Premier Research Names Etienne Drouet Executive Director, Oncology Europe 2
(Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor of ... campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing Practice ... the highest level of clinical nursing practice. , “Our vision is to graduate ...
(Date:8/27/2015)... ... August 27, 2015 , ... For the first ... machine with the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact ... that takes drink customization to a whole new level. This line of Nutri ...
(Date:8/27/2015)... ... ... Susan Harris and the team at LifeStream Health Centre & ... post-menopause, chemotherapy, and child birth. , The MonaLisa Touch is a unique ... tissue, revitalizing cells so they make more collagen, an essential component in vaginal cell ...
(Date:8/27/2015)... ... 27, 2015 , ... Since its launch on August 16, ... offices in three counties, LA, Orange and San Bernardino. Their twenty physicians ... by Dr. Richy Agajanian, the Oncology Institute of Hope and Innovation is dedicated ...
Breaking Medicine News(10 mins):Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2
... of a naturally occurring fat molecule have the potential ... or damage, researchers report. , Through both the ... smooth, young skin inevitably becomes coarse and wrinkled. The ... both lower the production of new collagen while increasing ...
... percent of patients who recently underwent liver transplantation ... factors included having had biliary-enteric anastomosis (choledocho-jejunal or ... more than four red blood cell units transfused. ... of Liver Transplantation, a journal by John Wiley ...
... internet pharmacies and life-saving medicines, purchased online was ... Global Forum ... June 5 The European Alliance for Access ... research report,-- The Counterfeiting Superhighway. The report revealed ...
... Reps. Pomeroy, Capito, Berkley Leading,Respective Chambers, Letter Effort ... to Seniors, Medicare-Financed Nursing Home Care, WASHINGTON, ... and Alliance for Quality Nursing Home Care today ... and Reps. Earl,Pomeroy (D-ND), Shelley Moore Capito (R-WV) ...
... June 5 Fort Dodge Animal Health, a,division of ... of,ProHeart(R) 6, a unique heartworm preventative, to the U.S. ... Food and Drug,Administration,s Center for Veterinary Medicine (CVM) of ... support the decision,to return this life-saving product to the ...
... to restore function to a paralyzed limb? Or to ... are two of the several topics that will be ... by Case Western Reserve University. The conference will be ... Conference Center in Cleveland. , "Neural interfaces have already ...
Cached Medicine News:Health News:Researchers determine risk factors for infection after liver transplantation 2Health News:Death on the Net? Over 60% of Medicines Sold by Online Pharmacies are Fake 2Health News:Death on the Net? Over 60% of Medicines Sold by Online Pharmacies are Fake 3Health News:AHCA, Alliance Praise New Bipartisan, Bi-Cameral Effort Urging Bush Administration to Forego Medicare Cuts 2Health News:AHCA, Alliance Praise New Bipartisan, Bi-Cameral Effort Urging Bush Administration to Forego Medicare Cuts 3Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 2Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 3Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 4Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 5Health News:Premier conference on neurotechnology and deep brain stimulation to be held in Cleveland June 16-18 2
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... Consensus knee system continues the "Consensus Concept" ... with the diversified experience of a Scientific ... knee system that incorporates state-of-the-art features. Consensus ... joint and implant stability and allow near ...
Profix total knee system is intended for cemented use only....
Medicine Products: